Arrowhead Pharmaceuticals
ARWR
$22.33
Share price
-1.24%
Change (1 day)
-26.55%
Change (1 year)
Categories
P/S ratio for Arrowhead Pharmaceuticals (ARWR)
P/S ratio as of April 2024 (TTM): 15.4
According to Arrowhead Pharmaceuticals 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 15.4138. At the end of 2023 the company had a P/S ratio of 18.1.
P/S ratio history for Arrowhead Pharmaceuticals from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 18.1 | 9.07% |
| 2022 | 16.6 | -65.44% |
| 2021 | 48.0 | -51.41% |
| 2020 | 98.8 | 151.89% |
| 2019 | 39.2 | 61.22% |
| 2018 | 24.3 | 169.8% |
| 2017 | 9.01 | -64.88% |
| 2016 | 25.7 | -98.22% |
| 2015 | > 1000 | 7.55% |
| 2014 | > 1000 | -44.71% |
| 2013 | > 1000 | 1936.39% |
| 2012 | 119 | -93.55% |
| 2011 | > 1000 | 12700.49% |
| 2010 | 14.4 | 39.13% |
| 2009 | 10.3 | -57.95% |
| 2008 | 24.6 | -72.88% |
| 2007 | 90.6 | -78.6% |
| 2006 | 424 | 111.8% |
| 2005 | 200 | 6.9% |
| 2004 | 187 | 547.7% |
| 2003 | 28.9 | 126.56% |
| 2002 | 12.7 | -11.98% |
| 2001 | 14.5 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 3.78 | -75.51% | 🇺🇸 USA |
 Moderna
MRNA | 5.78 | -62.49% | 🇺🇸 USA |
 Ligand Pharmaceuticals LGND | 9.78 | -36.56% | 🇺🇸 USA |
 Dicerna Pharmaceuticals DRNA | N/A | N/A | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | 10.0 | -34.86% | 🇺🇸 USA |
 Inovio Pharmaceuticals INO | 287 | 1,758.78% | 🇺🇸 USA |